Flagship Pioneering

Sail Biomedicines Provides Update on Research with Cystic Fibrosis Foundation and Pioneering Medicines

Retrieved on: 
금요일, 1월 5, 2024
Software, Research, General Health, Pharmaceutical, Data Management, Technology, Genetics, Artificial Intelligence, Health Technology, Clinical Trials, Science, Biotechnology, Health, RNA, Cystic Fibrosis Foundation, Nonsense, Messenger, Cystic fibrosis, Pancreas, Flagship Pioneering, MBA, Biomedicine, Infection, DSM-IV codes, CFTR

Sail Biomedicines, Inc., a Flagship Pioneering company and leader in RNA-based programmable medicines, today provided an update on its research funded by the Cystic Fibrosis Foundation (CF Foundation), with preclinical data that suggest that Sail’s Endless RNA™ (eRNA™) may offer the potential to treat the 10%-15% of people with CF for whom existing treatments are not an option.

Key Points: 
  • Sail Biomedicines, Inc., a Flagship Pioneering company and leader in RNA-based programmable medicines, today provided an update on its research funded by the Cystic Fibrosis Foundation (CF Foundation), with preclinical data that suggest that Sail’s Endless RNA™ (eRNA™) may offer the potential to treat the 10%-15% of people with CF for whom existing treatments are not an option.
  • Sail’s programmable eRNA platform is designed to enable the in vivo expression of any protein, potentially targeting any tissue.
  • Cystic fibrosis is a progressive, genetic disease caused by mutations in the CFTR gene that affect the lungs, pancreas, and other organs.
  • “We are extremely hopeful about the impact this work could have for the CF community.”
    “The collaboration between Pioneering Medicines and the Cystic Fibrosis Foundation aims to accelerate the path to potential treatments and cures for all people living with cystic fibrosis,” said Paul Biondi, President, Pioneering Medicines and Executive Partner, Flagship Pioneering.

Sail Biomedicines Appoints Tech and Pharma Industry Veteran Frank D’Amelio to Its Board

Retrieved on: 
목요일, 1월 4, 2024
Software, Research, General Health, Pharmaceutical, Data Management, Technology, Artificial Intelligence, Genetics, Health Technology, Science, Biotechnology, Health, RNA, Panasonic Executive Partner, Sale, CFO, Messenger, KKR, Acquisition, Medivation, Flagship Pioneering, MBA, Capsugel, Hospira, Biomedicine, Growth, Lucent, Management

Mr. D’Amelio brings to Sail’s board an accomplished record as a technology and pharmaceutical operations, finance and global supply executive.

Key Points: 
  • Mr. D’Amelio brings to Sail’s board an accomplished record as a technology and pharmaceutical operations, finance and global supply executive.
  • At Lucent, he played a critical role in its spinout from AT&T.
  • “I’m honored to be joining the Sail Biomedicines Board of Directors at a pivotal time for the company,” said Mr. D’Amelio.
  • “Sail’s vision and platform, which builds on over eight years of experimentation, represents an exciting opportunity to generate new medicines and forge innovative relationships with partners.

Novo Nordisk enters into research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases

Retrieved on: 
목요일, 1월 4, 2024
Biology, Ecosystem, Flagship, Partnership, Drug discovery, Risk, Research, Thermogenesis, Chemistry, Disease, Flagship Pioneering, Tissue, Pharming, Therapy, Novo Nordisk, AI, Appetite, Gene expression, Chronic liver disease, Obesity, Transplant, DSM-IV codes, Liver failure, OMEGA, Liver disease, Thermoregulation, Cardiovascular disease, Intelligence, Medicine, Pharmaceutical industry

4 January, 2024 – Novo Nordisk, Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”) and Cellarity Inc. today announced that Novo Nordisk has entered into separate research collaborations with each company.

Key Points: 
  • 4 January, 2024 – Novo Nordisk, Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”) and Cellarity Inc. today announced that Novo Nordisk has entered into separate research collaborations with each company.
  • These are the first two programmes signed under the framework collaboration between Flagship Pioneering and Novo Nordisk to leverage Flagship’s bioplatform companies to develop novel treatment approaches for cardiometabolic diseases.
  • “Novo Nordisk is committed to advancing new treatment options for people living with cardiometabolic diseases.
  • In September 2022, Novo Nordisk engaged Cellarity to identify novel cell behaviors implicated in MASH disease progression.

Generate:Biomedicines Fortifies Leadership in Generative AI with Advancing Clinical Pipeline and Expanded Amgen Collaboration, Overviewed at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
목요일, 1월 4, 2024
Software, Research, General Health, Pharmaceutical, Technology, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Other Technology, Other Science, Health, Westin St. Francis, Conference, Atopic dermatitis, Protein, Learning, Cryogenic electron microscopy, Flagship Pioneering, Gateway, AMGN, Generative, Biomedicine, Biomarker, SARS-CoV-2, Safety, Therapy, Vaccine

Mike Nally, Chief Executive Officer, will overview these updates, as well as share more about the company’s strategy to further strengthen its leadership in generative biology, at the 42nd Annual J.P. Morgan Healthcare Conference, which will be occurring from January 8-11 in San Francisco.

Key Points: 
  • Mike Nally, Chief Executive Officer, will overview these updates, as well as share more about the company’s strategy to further strengthen its leadership in generative biology, at the 42nd Annual J.P. Morgan Healthcare Conference, which will be occurring from January 8-11 in San Francisco.
  • The presentation will take place on January 10 from 10:00-10:25am PST at the Golden Gate (32nd Floor) of The Westin St. Francis.
  • Deploying structure in the learning loop utilizing CryoEM to generate data for iterative learning which has shown faster, improved outcomes.
  • “We look forward to working even more closely together in order to deliver best-in-class therapies that address significant unmet patient needs.”

Sail Biomedicines Receives Grants to Fight Malaria by Developing a New Class of RNA Medicines

Retrieved on: 
수요일, 1월 3, 2024
Oncology, Health, Infectious Diseases, Research, Science, Pharmaceutical, Biotechnology, RNA, Endless, Messenger, Melinda French Gates, Hook effect, Vaccine, Malaria, Flagship Pioneering, MBA, World Health Organization, Biomedicine, Bill

The World Health Organization estimates malaria kills more than 600,000 people worldwide each year.

Key Points: 
  • The World Health Organization estimates malaria kills more than 600,000 people worldwide each year.
  • This is based on innovative, translatable, circular RNA that, in preclinical studies, has demonstrated prolonged expression and greater immunogenicity than existing mRNA technology.
  • The aim is to produce a malaria vaccine that drives potent and longer-lasting active immunity, and is potentially more efficacious, than existing options.
  • The second grant supports a groundbreaking effort to deliver eRNA that expresses a monoclonal antibody for the prevention of malaria.

Cellarity to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
수요일, 1월 3, 2024
Health, Infectious Diseases, Technology, Health Technology, Artificial Intelligence, Pharmaceutical, Biotechnology, Research, Westin St. Francis, Conference, Flagship Pioneering

Cellarity Inc. , a life sciences company founded by Flagship Pioneering to fundamentally transform the way drugs are created and design medicines currently out of reach, announced today that Fabrice Chouraqui, CEO of Cellarity, will present a company overview, including recent business and research highlights, at the 42nd Annual J.P. Morgan Healthcare Conference at the Westin St. Francis on Thursday, January 11, 2024, at 7:30 a.m. PT.

Key Points: 
  • Cellarity Inc. , a life sciences company founded by Flagship Pioneering to fundamentally transform the way drugs are created and design medicines currently out of reach, announced today that Fabrice Chouraqui, CEO of Cellarity, will present a company overview, including recent business and research highlights, at the 42nd Annual J.P. Morgan Healthcare Conference at the Westin St. Francis on Thursday, January 11, 2024, at 7:30 a.m. PT.
  • A copy of the company’s presentation will be made available on the company’s website following the event.

Ampersand Biomedicines Acquires AbCheck to Accelerate Platform and Product Development

Retrieved on: 
수요일, 1월 3, 2024
Flagship, Partnership, Antibody, Protein engineering, Acquisition, Disease, Flagship Pioneering, Therapy, Navigation, Safety, Acceleration, Vaccine

The addition of AbCheck’s broad discovery platform and deep expertise in antibody generation and optimization will enable cost-effective and strategic acceleration of Ampersand’s Address, Navigate, Determine (AND)™ Platform.

Key Points: 
  • The addition of AbCheck’s broad discovery platform and deep expertise in antibody generation and optimization will enable cost-effective and strategic acceleration of Ampersand’s Address, Navigate, Determine (AND)™ Platform.
  • “This acquisition will boost the AND Platform and enhance Ampersand’s ability to generate multiple AND-Body™ Therapeutics in parallel.
  • Over the last 15 years, AbCheck has validated its platform through more than 45 partnerships with biopharma companies and produced multiple clinical candidates.
  • Through the acquisition, AbCheck will become a wholly-owned and independent unit of Ampersand.

Moa Technology hires for further growth with expansion of its leadership team – announcing appointment of CFO and US-based CBO to support advancement of next-generation herbicides

Retrieved on: 
월요일, 11월 20, 2023
Triangle Park (Quezon City), Corporation, Silence Therapeutics, Research, Research Triangle Park, Bachelor of Science, Business development, Therapy, CFO, Flagship Pioneering, University College Dublin, Biology, Bayer, GSK, Farmer, Health, Mergers and acquisitions, MBA, University, Growth, Doctor of Philosophy, Bioherbicide, Control, Newcastle University, Herbicide, CBO, Management, Pharmaceutical industry, Telescopic sight, Agriculture, Biochemistry, Syngenta, Apostolos, Moa

He has extensive experience of helping biotech companies raise funding, both through equity funding and industry collaborations.

Key Points: 
  • He has extensive experience of helping biotech companies raise funding, both through equity funding and industry collaborations.
  • His appointment also reflects Moa’s use of cutting-edge biotechnology processes to identify, understand and develop next-generation herbicides with game-changing speed and accuracy.
  • Without effective herbicides, farmers can lose up to 40% of their crop yield as a result of weed growth.
  • Dr. Virginia Corless, Chief Executive Officer of Moa Technology, says:
    “Moa is tackling a major crisis that threatens farmers’ livelihoods and global food security.

Cellarity Named a Top Place to Work for 2023 by The Boston Globe

Retrieved on: 
월요일, 12월 4, 2023
Software, Research, Professional Services, Pharmaceutical, Technology, Genetics, Artificial Intelligence, Publishing, Science, Biotechnology, Communications, Human Resources, Health, BBJ, Data science, Flagship Pioneering, Patient, Boston Business School, Systems biology, Drug discovery, Work, AI, Pharming, Drug development, Pharmaceutical industry, Wine Cellar Innovations

Top Places to Work recognizes the most admired workplaces in the state voted on by the people who know them best – their employees.

Key Points: 
  • Top Places to Work recognizes the most admired workplaces in the state voted on by the people who know them best – their employees.
  • The rankings in Boston Globe’s Top Places to Work are based on confidential survey information collected from more than 137,000 individuals at 341 Massachusetts organizations.
  • The survey measures employee opinions about their company's direction, execution, connection, management, work, pay and benefits, and engagement.
  • This achievement was based on the input from Cellarity team members who responded to the BBJ survey asking for their anonymous feedback on Cellarity as an employer.

Thermo Fisher Scientific & Flagship Pioneering Expand Ongoing Strategic Partnership to Jointly Create New Platform Companies with First-in-Class Enabling Technologies for Life Sciences

Retrieved on: 
화요일, 11월 28, 2023
Biotechnology, General Health, Biometrics, Health, Health Technology, Flagship Pioneering, Thermo Fisher Scientific, NYSE, Partnership, TMO, Organization, Mindful Scientific Inc., Environmental health, Ecosystem, Management, Flagship

Through this collaboration, Thermo Fisher and Flagship will work together to create new platform companies focusing on novel tools and capabilities that seek to power the biotech ecosystem and accelerate the development of first-in-class therapies.

Key Points: 
  • Through this collaboration, Thermo Fisher and Flagship will work together to create new platform companies focusing on novel tools and capabilities that seek to power the biotech ecosystem and accelerate the development of first-in-class therapies.
  • The newly formed strategic partnership is an expansion of the long-standing supply relationship between Thermo Fisher and Flagship, which extends to Flagship’s ecosystem of companies and leverages the expertise of both organizations including the areas of life science tools, diagnostics, and services.
  • “Our partnership will couple Flagship’s innovative company formation process with Thermo Fisher’s deep understanding of the life sciences industry, as we collaborate to develop transformative capabilities for the ecosystem.
  • We are pleased to expand our relationship with Thermo Fisher and together take bigger leaps in life sciences capabilities, while further empowering our industry.”